Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,486 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (402)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT04965454 | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma(ExTRACT-HCC) | recruiting | Phase 2 | 80 | Queen's Medical CenterOTHER | 1 | Aug 12, 2026 |
| clinicaltrials |
| NCT06549829 | the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma | recruiting | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors(SORB-PET) | recruiting | N/A | 50 | Peking University Third HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760038 | Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury | recruiting | N/A | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma(SLIDE-HCC) | recruiting | Phase 2 | 140 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06899152 | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | recruiting | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06904183 | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | recruiting | Phase 2 | 320 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03959800 | Molecular Basis of Pediatric Liver Cancer | recruiting | — | 1,600 | University of PittsburghOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07159048 | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors | recruiting | N/A | 120 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations(SURF201) | active not recruiting | Phase 1 | 40 | Tyra Biosciences, IncINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence(Neo-LENTIS) | recruiting | Phase 3 | 198 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748481 | Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for Subcapsular Hepatocellular Carcinoma | not yet recruiting | — | 180 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05168163 | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | recruiting | Phase 2 | 122 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07381634 | The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities | recruiting | Phase 2 | 134 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT05285358 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology(TARGETMONITO) | recruiting | N/A | 330 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06877637 | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer(BILLIONSTARS) | recruiting | — | 150 | Region SkaneOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation(CheckMate 9DX) | active not recruiting | Phase 3 | 545 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 31, 2026 | clinicaltrials |
| NCT04912765 | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | recruiting | Phase 2 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07268131 | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria(TITAN-HCC) | recruiting | N/A | 30 | Fudan UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04194775 | A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | active not recruiting | Phase 3 | 534 | CStone PharmaceuticalsINDUSTRY | 6 | Jul 30, 2026 | clinicaltrials |
| NCT04337177 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | active not recruiting | Phase 1 | 20 | Valent Technologies, LLCINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04712643 | A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | active not recruiting | Phase 3 | 342 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05621499 | HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | active not recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation(HCC-AI-RECLAIM) | not yet recruiting | N/A | 2,000 | Tongji HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT06710223 | Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | active not recruiting | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | recruiting | Phase 4 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | recruiting | Phase 1 / Phase 2 | 160 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma(HIMALAYA) | active not recruiting | Phase 3 | 1,324 | AstraZenecaINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07729618 | AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma(HCC-AI-SELECT) | not yet recruiting | N/A | 1,800 | Tongji HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06796114 | Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab(PREDICT-HCC) | recruiting | N/A | 120 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials